These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19766052)

  • 1. Recent development in carbohydrate-based cancer vaccines.
    Guo Z; Wang Q
    Curr Opin Chem Biol; 2009 Dec; 13(5-6):608-17. PubMed ID: 19766052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent advance in carbohydrate-based cancer vaccines].
    Huo CX; Ye XS
    Yao Xue Xue Bao; 2012 Mar; 47(3):261-70. PubMed ID: 22645748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines.
    Feng D; Shaikh AS; Wang F
    ACS Chem Biol; 2016 Apr; 11(4):850-63. PubMed ID: 26895482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate-based cancer vaccines: target cancer with sugar bullets.
    Liu CC; Ye XS
    Glycoconj J; 2012 Aug; 29(5-6):259-71. PubMed ID: 22669462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for cancer: synthetic carbohydrate-based vaccines.
    Buskas T; Thompson P; Boons GJ
    Chem Commun (Camb); 2009 Sep; (36):5335-49. PubMed ID: 19724783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic.
    Wilson RM; Danishefsky SJ
    J Am Chem Soc; 2013 Oct; 135(39):14462-72. PubMed ID: 23944352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse.
    Wang Q; Zhou Z; Tang S; Guo Z
    ACS Chem Biol; 2012 Jan; 7(1):235-40. PubMed ID: 22013921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers.
    Zhou Z; Mondal M; Liao G; Guo Z
    Org Biomol Chem; 2014 May; 12(20):3238-45. PubMed ID: 24728423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.
    Qiu L; Gong X; Wang Q; Li J; Hu H; Wu Q; Zhang J; Guo Z
    Cancer Immunol Immunother; 2012 Nov; 61(11):2045-54. PubMed ID: 22539085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines.
    Sungsuwan S; Yin Z; Huang X
    ACS Appl Mater Interfaces; 2015 Aug; 7(31):17535-44. PubMed ID: 26200668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.
    Hakomori S
    Adv Exp Med Biol; 2001; 491():369-402. PubMed ID: 14533809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbohydrate-based vaccines for oncotherapy.
    Wei MM; Wang YS; Ye XS
    Med Res Rev; 2018 May; 38(3):1003-1026. PubMed ID: 29512174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines.
    Grigalevicius S; Chierici S; Renaudet O; Lo-Man R; Dériaud E; Leclerc C; Dumy P
    Bioconjug Chem; 2005; 16(5):1149-59. PubMed ID: 16173792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.
    Yang F; Zheng XJ; Huo CX; Wang Y; Zhang Y; Ye XS
    ACS Chem Biol; 2011 Mar; 6(3):252-9. PubMed ID: 21121644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates.
    Huo CX; Zheng XJ; Xiao A; Liu CC; Sun S; Lv Z; Ye XS
    Org Biomol Chem; 2015 Mar; 13(12):3677-90. PubMed ID: 25679360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carrier diversity and chemical ligations in the toolbox for designing tumor-associated carbohydrate antigens (TACAs) as synthetic vaccine candidates.
    Roy R; Mousavifar L
    Chem Soc Rev; 2023 May; 52(10):3353-3396. PubMed ID: 37070256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic glycopeptides for the development of cancer vaccines.
    Liakatos A; Kunz H
    Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response.
    Song C; Zheng XJ; Guo H; Cao Y; Zhang F; Li Q; Ye XS; Zhou Y
    Glycoconj J; 2019 Oct; 36(5):399-408. PubMed ID: 31267246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.
    Pifferi C; Thomas B; Goyard D; Berthet N; Renaudet O
    Chemistry; 2017 Nov; 23(64):16283-16296. PubMed ID: 28845889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.